- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02002468
Follow-up of Abnormal and Inadequate Smear-test Results
Follow-up of Abnormal and Inadequate Test Results in the Danish Cervical Cancer Screening Program.
Denmark has a higher incidence of cervical cancer than other Nordic countries, although all Danish women (aged 23-65) are screened regularly to identify possible cervical dysplasia or asymptomatic invasive cancer.
Annually 40 000 women receives an abnormal or inadequate test result and a follow-up recommendation.
However problems with delayed follow-up may threaten the effectiveness of the Danish Cervical Cancer Screening Program, as 20% of women are delayed and dysplasia potentially can progress into cancer.
Delayed follow-up is found in situations where women either consciously or unconsciously postpone follow-up, or because of organizational aspects of the screening program, where communication regarding test results can fail either in content or with delay.This study will evaluate two interventions designed to increase follow-up:
- A letter with the test result and potential recommendation for follow up will be sent to the women (RCT). The intention is to ensure that all women will be notified about the test result, quickly, homogenously and in layman's written language, still with the opportunity to contact or be contacted by the general practitioner, if there is special needs. Furthermore, it is assumed that general practitioner consultations regarding delivery of normal test results will decrease, so that cost savings is a potential side benefit
- Electronic reminder to the general practitioner if women have not had the recommended follow up, giving the general practioner´s an opportunity to remind the women (retro perspective cohort study).
The results will be of great importance to the future organisation of cervical and colorectal cancer screening programmes in Denmark, but will also have international interest because of their similar challenges.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Central Denmark Region
-
Aarhus, Central Denmark Region, Danmark, 8000
- University of Aarhus
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- woman with a pap-smear test
Exclusion Criteria:
- less than 23 years
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Test result sent by letter
The pap-smear test result is sent by letter directly to the women.
Women in need of follow up are in the letter recommended to contact their general practitioner.
|
|
Aktiv komparator: Test result conveyed by general practitioners
In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of women with timely follow-up
Tidsramme: 1½ year
|
The proportion of women followed up will be calculated as cumulated incidence proportions according to four timeframes (undesirable early, as recommended, late, very late), and be compared by relative risks.
The results will be presented in totals and separately depending on the test result (normal/inadequate/Bethesda classification 2001/HPV).
|
1½ year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Frequency of general practitioner contacts (consultations/telephone calls /e-mails) regarding conveying the smear test result.
Tidsramme: Three months after the smear test.
|
The two randomisation groups will be compared with respect to contacts with general practitioner after the smear test the first days, weeks, months after the general practitioner is notified of the screening result.
|
Three months after the smear test.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Peter Vedsted, Center for Research in Cancer Diagnosis in Primary Care - (CaP), Aarhus University
- Studieleder: Flemming Bro, The Research Unit of General Practice in Aarhus, Aarhus University
- Studieleder: Berit S Andersen, The Department of Public Health Programmes at Regional Hospital Randers
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Cervix cancer screening
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Karsinom in situ av livmorhalsen
-
Mithra PharmaceuticalsFullførtIntraepitelial neoplasi i livmorhalsen | Uterin cervikal neoplasiBelgia
-
Peking University Cancer Hospital & InstituteUkjentEsophageal plateepitelkarsinom | Mild dysplasi i spiserøret | Moderat dysplasi i spiserøret | Alvorlig dysplasi i spiserøret | Carcinoma in situ of esophagusKina
-
University Hospitals Cleveland Medical CenterFullførtLivmor livmorhalsdysplasi | Livmor livmorhalskreft | Uterin cervikal neoplasi | Uterine Cervical Intraepithelial Neoplasia
-
University of AarhusFullførtUterine cervikale neoplasmer | Livmor livmorhalsdysplasi | Normal uterin cervikal cytologiDanmark
-
UNC Lineberger Comprehensive Cancer CenterHar ikke rekruttert ennåLivmorhalskreft | Cervix Intraepitelial Neoplasia Grad 3 | Livmorhalsen; Intraepitelial neoplasi, grad I | Livmorhalsen; Intraepitelial neoplasi, grad IIKenya
-
Alkü Alanya Education and Research HospitalUkjentEndometriehyperplasi | Uterin fibroid | Cervikal dysplasi | EggstokkcysteTyrkia
-
University Hospital, ToursFullførtKjønnssykdommer, kvinner | Livmorprolaps | Dysfunksjonell livmorblødning | Cervikal dysplasi | Hysterotomi; Påvirker fosteret | Leiomyomata Uteri | Adenomyose, EndometrioseFrankrike
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage IV prostatakreft AJCC v8 | Hepatobiliær neoplasma | Stadium III nyrecellekreft AJCC v8 | Stadium IV nyrecellekreft AJCC v8 | Stage III Livmor Corpus Cancer AJCC v8 | Stage IV Livmor Corpus Cancer AJCC v8 | Stage IVA Livmor Corpus Cancer AJCC v8 | Stadium IVB Uterine Corpus Cancer AJCC v8 | Ondartet... og andre forholdForente stater
Kliniske studier på Test result sent by letter
-
Dar El Oyoun HospitalUkjentGrå stær | Bivirkningshendelse | MydriasisEgypt
-
National Cancer Institute (NCI)NRG OncologyFullførtCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical plateepitelkarsinom | Tilbakevendende livmorhalskreft | Stadium IVB LivmorhalskreftForente stater, Spania